Last reviewed · How we verify
Escitalopram+Mirtazapine
This combination enhances serotonin and norepinephrine signaling while blocking serotonin autoreceptors and histamine receptors to improve mood and reduce anxiety.
This combination enhances serotonin and norepinephrine signaling while blocking serotonin autoreceptors and histamine receptors to improve mood and reduce anxiety. Used for Major depressive disorder, Anxiety disorders.
At a glance
| Generic name | Escitalopram+Mirtazapine |
|---|---|
| Also known as | lexapro, remeron |
| Sponsor | Ministry of Health & Welfare, Korea |
| Drug class | Antidepressant combination (SSRI + NaSSA) |
| Target | Serotonin transporter (SERT), norepinephrine transporter (NET), alpha-2 adrenergic receptors, histamine H1 receptors |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Mental Health |
| Phase | FDA-approved |
Mechanism of action
Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking its reuptake. Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) that blocks alpha-2 adrenergic autoreceptors and H1 histamine receptors, thereby increasing norepinephrine and serotonin release while promoting sedation. Together, they provide complementary mechanisms for treating depression and anxiety disorders.
Approved indications
- Major depressive disorder
- Anxiety disorders
Common side effects
- Sedation/somnolence
- Weight gain
- Sexual dysfunction
- Nausea
- Headache
- Dizziness
- Dry mouth
Key clinical trials
- Treating Negative Affect in Low Back Pain Patients (PHASE2, PHASE3)
- Neurobiological and Genomic Predictors of Relapse in Depression
- Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (PHASE2)
- A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression (PHASE3)
- Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea
- Psychopharmacotherapy for Depressive Patients (NA)
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Escitalopram+Mirtazapine CI brief — competitive landscape report
- Escitalopram+Mirtazapine updates RSS · CI watch RSS
- Ministry of Health & Welfare, Korea portfolio CI